117 related articles for article (PubMed ID: 8256764)
1. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.
Barrett RJ; Blessing JA; Homesley HD; Twiggs L; Webster KD
Am J Clin Oncol; 1993 Dec; 16(6):494-6. PubMed ID: 8256764
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
3. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
7. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin.
Deppe G; Malviya VK; Malone JM; Christensen CW; Saunders D
Eur J Gynaecol Oncol; 1994; 15(4):263-6. PubMed ID: 7957332
[TBL] [Abstract][Full Text] [Related]
8. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
[TBL] [Abstract][Full Text] [Related]
9. Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
Hall DJ; Martin DA; Kincaid K
Eur J Gynaecol Oncol; 2003; 24(6):481-9. PubMed ID: 14658586
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Walker JL; Moore KN; Waggoner SE; Thaker PH; Rizack T; Hoffman JS; Fracasso PM
Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Filiaci VL; Bentley RC; Herzog T; Sorosky J; Vaccarello L; Gallion H
Ann Oncol; 2004 Aug; 15(8):1173-8. PubMed ID: 15277255
[TBL] [Abstract][Full Text] [Related]
15. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
16. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
Randall ME; Filiaci VL; Muss H; Spirtos NM; Mannel RS; Fowler J; Thigpen JT; Benda JA;
J Clin Oncol; 2006 Jan; 24(1):36-44. PubMed ID: 16330675
[TBL] [Abstract][Full Text] [Related]
18. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
[TBL] [Abstract][Full Text] [Related]
19. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
Honma H; Sagae S; Terasawa K; Tanaka R; Chida M; Mizumoto H; Ishioka S; Saito T; Kudo R
Gan To Kagaku Ryoho; 2004 Apr; 31(4):549-53. PubMed ID: 15114698
[TBL] [Abstract][Full Text] [Related]
20. [A feasibility study of doxorubicin/cisplatin (AP) for postoperative chemotherapy in patients with advanced endometrial cancer].
Nishio S; Katsumata N; Tanabe H; Matsumoto K; Yonemori K; Kouno T; Shimizu C; Ando M; Fujiwara Y
Gan To Kagaku Ryoho; 2006 Nov; 33(11):1589-93. PubMed ID: 17108724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]